Use of Methacetin Breath Test to Predict Liver Failure in Patients With Cirrhosis
- Conditions
- Cirrhosis
- Interventions
- Device: BreathID (Methacetin breath test)
- Registration Number
- NCT01157845
- Lead Sponsor
- Virginia Commonwealth University
- Brief Summary
The methacetin breath test (MBT) is a non-invasive liver function test which measures the ability of the liver to metabolize a tracer dose of a compound to carbon dioxide, which is exhaled. The study hypothesis is that measurement of the MBT will allow earlier detection of a decline in liver function in patients with cirrhosis who are awaiting liver transplantation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 165
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Laboratory assay BreathID (Methacetin breath test) -
- Primary Outcome Measures
Name Time Method Mortality From Liver Failure 1 year Patient dies of liver-related causes within 1 year of study entry
- Secondary Outcome Measures
Name Time Method Liver Transplantation 1 year Patient experiences complications of liver failure within 1 year of study entry and undergoes liver transplantation
Trial Locations
- Locations (4)
Henry Ford Health System
🇺🇸Detroit, Michigan, United States
Medical University of South Carolina
🇺🇸Charleston, South Carolina, United States
Hadassah Medical Center
🇮🇱Jerusalem, Israel
Virginia Commonwealth University Medical Center
🇺🇸Richmond, Virginia, United States